CD274 and gastroesophageal junction adenocarcinoma: Importantly, the difference in OS between PD‐L1 inhibitors and PD‐1 inhibitors approached significance (HR = 0.99 and 0.77, respectively, p for the subgroup difference 0.08), suggesting possible improved efficacy of PD‐1 inhibitors in gastric or GEJ adenocarcinoma, though this difference was not statistically significant.